Peptide Drugs, Overcoming the Challenges, a Growing Business
Mimoun Ayoub and Daniel Scheidegger
Are low-Priced Peptides Affordable?
Rodney Lax and Michael Verlander
Libraries of Conformationally Restricted and Rigid Amino Acids
Igor V. Komarov, Oleksandr O. Grygorenko, Dmytro S. Radchenko, Oleksiy S. Artamonov, Alexander N. Kostyuk, and Andrey A. Tolmachev

DiaKine Therapeutics and Kinexum Metabolics to Develop Combination Treatment to Type 1 Diabetes
DiaKine’s Lisofylline and Kinexum’s INGAP peptide combo therapy is set for Phase 2 clinical trial.

CreoSalus Names New President
CreoSalus have named Craig Kalmer as President/CEO of the Advanced ChemTech and ThuraMed divisions of CreoSalus.

AnaSpec’s Published References Passes 600
As compiled by Stanford University’s Highwire Press, the number of published papers that cite AnaSpec’s products has passed 600.

Compugen Announces Discovery of Blood Based Biomarker for Diagnosis of Lung Cancer
Compugen discovers the peptide, a potential blood based biomarker for lung cancer, using its immunoassay diagnostics discovery platform.

A Novel Fluorimetric Assay for the Detection of TACE (a-Secretase)
AnaSpec, Inc.

To facilitate high throughput screening of TACE inhibitors, AnaSpec synthesized a novel peptide substrate for TACE using QXL™ 520/5-FAM FRET pair. Using this FRET substrate, AnaSpec developed a new kit – the SensoLyte™ 520 TACE Activity Assay. This kit can be used to detect the activity of the enzyme and for screening of TACE inhibitors. It is highly sensitive and can detect subnanogram amounts of enzyme.

Involvement of enkephalins and delta-opioid receptors in the expression of levodopa-induced dyskinesia in a model of hemiparkinsonian rat
Laboratory of Experimental Neuropharmacology

This study was performed to test the involvement of d-opioid receptors in dyskinesia induced by L-DOPA in hemiparkinsonian rats. Our results indicate that endogenous enkephakins modulate the expression of L-DOPA-induced dyskinesia. It also appears that d-opioid receptors located on corticostriatal terminals could be involved in the development of these dyskinesia. These results confer on d-opioid antagonists interesting properties in the improvement of Parkinson’s disease therapy.

Permanent Senior Scientist Position in NMR-based Metabolomics
CIBERDEM
Tarragona, Spain

BBSRC Funded Microfluidics Engineering Resarch PhD
University College London
London, UK

Post-Doctpral Position in Mollusk Health Laboratory
UPEI
Charlottetown, Canada

Production Chemist II
Independent
Torrance, CA, USA

Research Chemist
Independent
Torrance, CA, USA

phD Scholarship in BioInformatics
Universitat Rovira i Virgili
Tarragona, Spain

QC Analyst
Genomic Health
Redwood City, CA, USA

Research Scientist II - Biology
Gilead Sciences
Foster City, CA, USA

High Throughput Coordinator / Engineer
AJI
Houston, TX, USA

IBC’s TIDES®: Oligonucleotide and Peptide® Technology and Product Development, Las Vegas, NV, USA
18 May 2008 - 21 May 2008

TIDES® is the all encompassing conference on manufacturing, formulation, delivery, process and analytical development, as well as overall market trends for peptides and oligonucleotides. In addition to gaining scientific updates in conference sessions, you can develop and maintain your professional skills with two tracks focusing on oligos and peptides.

Global Protein Summit, London, UK
02 June 2008 - 03 June 2008

SMi’s 4th annual Global Protein Summit is designed to meet the needs of the industry. It will be an excellent opportunity to hear about the latest developments from leaders in the field, bringing together experts in protein expression, purification, identification and functional analysis.

RNAi, siRNA & miRNA, London, UK
11 June 2008 - 12 June 2008

The SMi Group are proud to present their 3rd RNAi, siRNA and miRNA 2008 conference. This conference offers a unique opportunity to hear about the latest developments from both industry leaders and academic research. The conference will address developments in understanding biology of RNAi and its potential applications in gene function analysis and therapy, as well as siRNA and the fascinating new developments in the world of miRNAs.
  


Evolution of Phage Display: From Bioactive Peptides to Bioselective Nanomaterials

Valery Petrenko, Professor, Auburn University, speaking at MedChem Europe 2007


Glycans and Peptides for Detection of Hepatocellular Carcinoma

Radoslav Goldman, Assistant Professor, Georgetown University, speaking at Proteomics Europe 2007


A Search for a Biomarker for Monitoring and Predicting Diabetes

Salvatore Sechi, Director, Proteomic Program, NIDDK, NIH, speaking at the European Biomarker Summit, 2007


Use of Human Plasma Depletion Technology and Antibody Arrays for the Rapid Detection of Biomarkers in Human Serum Samples

Richard Pembrey, Functional Proteomics Segment Manager, Sigma Aldrich, speaking at the European Biomarkers Summit, 2007

Peptides 2006 - New Applications in Discovery, Manufacturing, and Therapeutics
Published June 2006

Peptides 2006 analyzes the current peptide market. It features an analysis of therapeutic peptide products in multiple disease indications, as well as an up to date overview of key patent issues in this space.

Organic and Medicinal Chemistry in Drug Discovery
Published October 2005

D&MD's Organic and Medicinal Chemistry in Drug Discovery market analysis report investigates the methods and technologies currently used to craft compound collections as well as the products and services available to support pharmaceutical chemistry programs.